JP2019501222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501222A5 JP2019501222A5 JP2018554640A JP2018554640A JP2019501222A5 JP 2019501222 A5 JP2019501222 A5 JP 2019501222A5 JP 2018554640 A JP2018554640 A JP 2018554640A JP 2018554640 A JP2018554640 A JP 2018554640A JP 2019501222 A5 JP2019501222 A5 JP 2019501222A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- item
- methyl
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C*[C@@]1COCC1 Chemical compound C*[C@@]1COCC1 0.000 description 13
- LVEIJLGSXRYDEY-UHFFFAOYSA-N CC(C)c1c[nH]nn1 Chemical compound CC(C)c1c[nH]nn1 LVEIJLGSXRYDEY-UHFFFAOYSA-N 0.000 description 1
- ZLVYAWVDOLLMSD-UHFFFAOYSA-N CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1nc(-c(cc2)c(cc[nH]3)c3c2C(N)=O)ccn1 Chemical compound CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1nc(-c(cc2)c(cc[nH]3)c3c2C(N)=O)ccn1 ZLVYAWVDOLLMSD-UHFFFAOYSA-N 0.000 description 1
- XFSTWIDWOQOLIQ-UHFFFAOYSA-N CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1nc(-c2c(cc[n]3C)c3cc(C(N)=O)c2)ccn1 Chemical compound CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1nc(-c2c(cc[n]3C)c3cc(C(N)=O)c2)ccn1 XFSTWIDWOQOLIQ-UHFFFAOYSA-N 0.000 description 1
- RHSWKSOLSABYHY-UHFFFAOYSA-N CN(C)CCN(C)c(cc(c(Nc(nc1)nc(-c2c(cc[n]3C)c3cc(C(N)=O)c2)c1Cl)c1)OC)c1NC(C=C)=O Chemical compound CN(C)CCN(C)c(cc(c(Nc(nc1)nc(-c2c(cc[n]3C)c3cc(C(N)=O)c2)c1Cl)c1)OC)c1NC(C=C)=O RHSWKSOLSABYHY-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- YBOQHGVVMRFVDJ-UHFFFAOYSA-N SC1COCC1 Chemical compound SC1COCC1 YBOQHGVVMRFVDJ-UHFFFAOYSA-N 0.000 description 1
- JRKNQYISGWCMNB-UHFFFAOYSA-N SCC1COCC1 Chemical compound SCC1COCC1 JRKNQYISGWCMNB-UHFFFAOYSA-N 0.000 description 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N Sc1ccccc1 Chemical compound Sc1ccccc1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276221P | 2016-01-07 | 2016-01-07 | |
| US62/276,221 | 2016-01-07 | ||
| US201662399730P | 2016-09-26 | 2016-09-26 | |
| US62/399,730 | 2016-09-26 | ||
| PCT/US2017/012466 WO2017120429A1 (en) | 2016-01-07 | 2017-01-06 | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021029700A Division JP2021091703A (ja) | 2016-01-07 | 2021-02-26 | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501222A JP2019501222A (ja) | 2019-01-17 |
| JP2019501222A5 true JP2019501222A5 (enExample) | 2020-01-23 |
Family
ID=59274526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554640A Withdrawn JP2019501222A (ja) | 2016-01-07 | 2017-01-06 | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
| JP2021029700A Ceased JP2021091703A (ja) | 2016-01-07 | 2021-02-26 | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021029700A Ceased JP2021091703A (ja) | 2016-01-07 | 2021-02-26 | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10435388B2 (enExample) |
| EP (1) | EP3399968B8 (enExample) |
| JP (2) | JP2019501222A (enExample) |
| KR (1) | KR20180105161A (enExample) |
| CN (1) | CN109328059B (enExample) |
| TW (1) | TWI726968B (enExample) |
| WO (1) | WO2017120429A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117185B (zh) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| CN108602802B (zh) * | 2016-07-26 | 2020-01-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| TWI771319B (zh) | 2016-09-09 | 2022-07-21 | 美商英塞特公司 | 吡唑并吡啶化合物及其用途 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TWI808977B (zh) * | 2017-06-13 | 2023-07-21 | 大陸商北京浦潤奧生物科技有限責任公司 | 胺基嘧啶類化合物及其製備方法和用途 |
| EP3648753A4 (en) * | 2017-07-05 | 2021-03-17 | CS Pharmatech Limited | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE |
| CA3071345A1 (en) * | 2017-07-28 | 2019-01-31 | Yale University | Anticancer drugs and methods of making and using same |
| CN111295381A (zh) * | 2017-07-28 | 2020-06-16 | 株式会社柳韩洋行 | 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法 |
| CN108947974B (zh) * | 2017-08-30 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途 |
| CN109503573A (zh) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2-取代苯胺基嘧啶衍生物及其用途 |
| CN107827875B (zh) * | 2017-09-25 | 2021-07-09 | 文韬创新药物研究（北京）有限责任公司 | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
| WO2019154177A1 (zh) * | 2018-02-12 | 2019-08-15 | 恩瑞生物医药科技（上海）有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| US20200375999A1 (en) * | 2018-02-20 | 2020-12-03 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
| JP2021514011A (ja) * | 2018-02-20 | 2021-06-03 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US20210292333A1 (en) | 2018-06-15 | 2021-09-23 | Cadila Healthcare Limited | Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria |
| CN110790749B (zh) * | 2018-08-03 | 2023-07-14 | 北京普祺医药科技股份有限公司 | 一种含氮杂环化合物、药物组合物以及其用途 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN110857292A (zh) * | 2018-08-22 | 2020-03-03 | 上海艾力斯医药科技有限公司 | 一种egfr激酶抑制剂及其制备方法和应用 |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| CN111410651B (zh) * | 2019-01-05 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂的盐及其晶型 |
| CN113227073B (zh) * | 2019-01-05 | 2022-09-16 | 山东轩竹医药科技有限公司 | Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型 |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| EP3943491B1 (en) | 2019-03-19 | 2025-06-18 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| CN111825658B (zh) * | 2019-04-18 | 2024-11-08 | 华东理工大学 | Egfr三突变抑制剂及其应用 |
| CN112174961A (zh) * | 2019-07-04 | 2021-01-05 | 微境生物医药科技(上海)有限公司 | 一类抑制egfr激酶的化合物及其制备方法和用途 |
| AU2020322881B2 (en) * | 2019-07-26 | 2023-08-10 | China Resources Pharmaceutical Holdings Company Limited | Pyrimidine compound acting on EGFR and ERBB2 |
| PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
| CN113179640B (zh) * | 2019-11-26 | 2024-06-25 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| CN113045475A (zh) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | 一种5-溴-7-甲基吲哚的制备方法 |
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| WO2021243596A1 (en) * | 2020-06-03 | 2021-12-09 | InventisBio Co., Ltd. | Aminopyrimidine compounds, preparation methods and uses thereof |
| CN114249712A (zh) * | 2020-09-24 | 2022-03-29 | 广州费米子科技有限责任公司 | 嘧啶基衍生物、其制备方法及其用途 |
| EP4225309A4 (en) * | 2020-10-12 | 2024-12-25 | Dana-Farber Cancer Institute, Inc. | COVALENT INHIBITORS OF EGFR AND METHODS OF USE THEREOF |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| CN114539269B (zh) * | 2020-11-19 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种含氮大环化合物、其制备方法及其应用 |
| US20240002378A1 (en) * | 2020-11-30 | 2024-01-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Merged scaffold taf1 inhibitors |
| US20240109885A1 (en) * | 2020-12-02 | 2024-04-04 | Abbisko Therapeutics Co., Ltd | 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivative, preparation method therefor, and application thereof |
| WO2022271846A1 (en) * | 2021-06-23 | 2022-12-29 | Blueprint Medicines Corporation | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
| CN117881670A (zh) * | 2021-06-23 | 2024-04-12 | 缆图药品公司 | 制备egfr抑制剂的方法 |
| CN115701429B (zh) * | 2021-08-02 | 2024-03-12 | 上海和誉生物医药科技有限公司 | 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用 |
| CN117440945A (zh) * | 2021-08-06 | 2024-01-23 | 上海和誉生物医药科技有限公司 | 嘧啶或吡啶衍生物及其制备方法和在药学上的应用 |
| CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
| CN116283914A (zh) * | 2021-12-01 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类嘧啶类化合物、其制备方法及应用 |
| WO2026047630A1 (en) * | 2024-08-31 | 2026-03-05 | Hetero Labs Limited | Heterocyclic compounds as egfr inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| AU725548B2 (en) | 1997-03-11 | 2000-10-12 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| WO2010142934A1 (en) | 2009-06-12 | 2010-12-16 | Pulmagen Therapeutics (Asthma) Limited | Indole derivatives as ligands of crth2 receptors |
| EP2736895B1 (en) | 2011-07-27 | 2016-01-06 | Astrazeneca AB | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| NZ729443A (en) | 2012-07-03 | 2017-11-24 | 3-V Biosciences Inc | Heterocyclic modulators of lipid synthesis |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CN104761544B (zh) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
| CN106660993B (zh) | 2014-06-12 | 2020-09-11 | 上海复尚慧创医药研究有限公司 | 一类激酶抑制剂 |
| PE20170268A1 (es) | 2014-06-19 | 2017-04-21 | Ariad Pharma Inc | Compuestos de heteroarilo para la inhibicion de cinasa |
| CN105315259B (zh) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CN106458969A (zh) | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN105461695B (zh) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| RU2702631C2 (ru) * | 2014-10-11 | 2019-10-09 | Шанхай Хэнсох Биомедикал Ко., Лтд. | Ингибитор egfr и его получение и применение |
| MX2017003181A (es) | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| WO2016102076A1 (de) | 2014-12-23 | 2016-06-30 | Mitsubishi Hitec Paper Europe Gmbh | Wärmeempfindliches aufzeichnungsmaterial zur offset-bedruckung |
| US10266517B2 (en) | 2014-12-23 | 2019-04-23 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
| CN104788427B (zh) | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| CN104844580B (zh) | 2015-04-17 | 2017-10-20 | 中国药科大学 | 嘧啶类化合物、其制备方法及医药用途 |
| JP6457697B2 (ja) | 2015-04-29 | 2019-01-23 | カントン チョンション ファーマシューティカル カンパニー，リミティド | キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物 |
| EP3294712A4 (en) | 2015-05-13 | 2018-11-07 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| JP6970081B2 (ja) | 2015-07-16 | 2021-11-24 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | アニリンピリミジン誘導体及びその使用 |
| CN105001208A (zh) | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | 一种表皮生长因子受体egfr抑制剂及其制备方法与用途 |
| CN106117185B (zh) | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
| CN106749193B (zh) | 2015-11-23 | 2020-11-20 | 南京圣和药业股份有限公司 | 吲唑取代的表皮生长因子受体抑制剂及其应用 |
| CN106928150B (zh) | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| CN106279160B (zh) | 2016-03-18 | 2017-09-26 | 海南越康生物医药有限公司 | N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途 |
| WO2017190637A1 (zh) | 2016-05-06 | 2017-11-09 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物 |
| US11052086B2 (en) | 2016-05-11 | 2021-07-06 | Beta Pharma, Inc. | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
| CN108602802B (zh) | 2016-07-26 | 2020-01-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| EP3648753A4 (en) | 2017-07-05 | 2021-03-17 | CS Pharmatech Limited | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE |
-
2017
- 2017-01-06 EP EP17736401.5A patent/EP3399968B8/en not_active Not-in-force
- 2017-01-06 WO PCT/US2017/012466 patent/WO2017120429A1/en not_active Ceased
- 2017-01-06 TW TW106100545A patent/TWI726968B/zh not_active IP Right Cessation
- 2017-01-06 US US16/068,559 patent/US10435388B2/en active Active
- 2017-01-06 CN CN201780016875.2A patent/CN109328059B/zh active Active
- 2017-01-06 KR KR1020187022731A patent/KR20180105161A/ko not_active Withdrawn
- 2017-01-06 JP JP2018554640A patent/JP2019501222A/ja not_active Withdrawn
-
2021
- 2021-02-26 JP JP2021029700A patent/JP2021091703A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501222A5 (enExample) | ||
| JP2020526499A5 (enExample) | ||
| AU2017272286B2 (en) | Methods for improving diaphragm function | |
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| JP6586098B2 (ja) | キナーゼ阻害剤としてのピラゾリル尿素 | |
| JP2026506637A (ja) | がんの治療のための三環式化合物 | |
| JP2013539777A5 (enExample) | ||
| BR112021023277A2 (pt) | Formas em estado sólido | |
| ES2635003T3 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET | |
| JP2017524702A5 (enExample) | ||
| CN101605540A (zh) | 使用mek抑制剂的方法 | |
| JP2009529047A5 (enExample) | ||
| CA2895404A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
| AU2017286654A1 (en) | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | |
| CA2709786A1 (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
| JP2011520832A5 (enExample) | ||
| KR20180058832A (ko) | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 | |
| JP2005529092A5 (enExample) | ||
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| TR201802725T4 (tr) | İlaç kombinasyonu. | |
| CA2749040A1 (en) | Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd | |
| JP2011512395A (ja) | 組合せ療法２３８ | |
| EA038071B1 (ru) | СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53 | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция |